Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence

Obesity Science and Practice

Volumn 3, Issue 3, 2017, Pages 342-351

  Carls, G S ^a   Tan, R ^a   Zhu, J Y ^a   Tuttle, E ^a   Yee, J ^b   Edelman, S V ^c,d   Polonsky, W H ^e,f  

^a ANALYSIS GROUP   (United States)

^b Research Triangle   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Taking Control of Your Diabetes   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Behavioral Diabetes Institute   (United States)

Author keywords

Medication adherence; real world; type 2 diabetes; weight change

Indexed keywords

ALOGLIPTIN; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; LINAGLIPTIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN;

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 85050015537     PISSN: None     EISSN: 20552238     Source Type: Journal    
DOI: 10.1002/osp4.116     Document Type: Article

References (24)

1. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2008; 52: 65–73.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–1379.
3. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481–1486.
4. Appel LJ, Clark JM, Yeh H-C, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011; 365: 1959–1968.
5. Wadden TA, Volger S, Sarwer DB, et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 2011; 365: 1969–1979.
6. Espeland M. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374–1383.
7. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity 2014; 22: 5–13.
8. Wilding J. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014; 68: 682–691.
9. American Diabetes Association. Standards of medical care in diabetes—2017. Diabetes Care 2017; 40: S57–S63.
10. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140–149.
11. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012; 344: d7771.
12. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract; 109: 378–388.
13. Farr AM, Sheehan JJ, Curkendall SM, et al. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther 2014; 31: 1287–1305.
14. Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther 2015; 32: 341–355.
15. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011; 33: 74–109.
16. Medicare 2015 part C & D star rating technical notes. Centers for Medicare & Medicaid Services (CMS); 2015.
17. NQF-endorsed measures for endocrine conditions, 2013–2015: final report. Technical report. Washington, DC: National Quality Forum; 2016.
18. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836–1841.
19. Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther 2014; 31: 986–999.
20. Grandy S, Fox KM, Hardy E, Group SS. Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes). Curr Ther Res Clin Exp 2013; 75: 77–82.
21. McAdam-Marx C, Mukherjee J, Bellows BK, et al. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Clin Pract 2014; 103: 402–411.
22. Mukherjee J, Sternhufvud C, Smith N, et al. Association between weight change, clinical outcomes, and health care costs in patients with type 2 diabetes. J Manag Care Spec Pharm 2016; 22: 449–466.
23. Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2016; 19: 524–536.
24. Singh S, Wright EE, Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2016; 19: 228–238.